SCHEMBL18806181

SCHEMBL18806181

COCCN1CCc2nc(C(C)(C)C)ccc2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 2/20 0.40
▸ FLT3 P36888 1/20 0.40
▸ CDK1 P06493 1/20 0.39
▸ CCNB1 P14635 1/20 0.39
▸ CCNE1 P24864 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ CDK7 P50613 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ CDK6 Q00534 1/20 0.39
▸ ATR Q13535 1/20 0.37
▸ FFAR1 O14842 1/20 0.37
▸ PDCD1 Q15116 4/20 0.36
▸ CD274 Q9NZQ7 4/20 0.36
▸ MAPT P10636 3/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ LMNA P02545 3/20 0.35
▸ POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20249376 0.84 PDCD1 (0.47) CDK4FLT3CDK1CDK2CDK7
SCHEMBL18820431 0.82 CDK4 (0.42) CDK4FLT3CDK1CCNB1CCNE1
SCHEMBL20255390 0.82 CDK4 (0.43) CDK4CDK1CDK2CDK7CDK9
SCHEMBL22966559 0.82 CDK4 (0.42) CDK4CDK2CDK6MAPTLMNA
SCHEMBL18806194 0.82 ADORA2A (0.37) CDK4FLT3CDK1CDK2CDK7
SCHEMBL18819904 0.82 CDK4 (0.41) CDK4FLT3PDCD1CD274MAPT
SCHEMBL20249391 0.82 CDK4 (0.42) CDK4CDK1CCNB1CCNE1CDK2
SCHEMBL22966560 0.80 CDK4 (0.41) CDK4CDK2CDK6PDCD1CD274
SCHEMBL18806155 0.80 CDK4 (0.44) CDK4FLT3CDK2CDK6LMNA
SCHEMBL23554843 0.79 CDK4 (0.42) CDK4FLT3CDK1CCNB1CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828373-B2 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-11-28 — — US disclosed
US-9828373-B2 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-11-28 — — US disclosed
US-20170121323-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-05-04 — — US disclosed
US-20170121323-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121323-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF CDK6, CDK4, CDK7 CDK4 2/4885FLT3 825/4885CDK1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback